News
15 Jun 2026
Novartis launches Pluvicto®, the Country’s First Regulatory Authority Approved Radioligand Therapy for Advanced Prostate Cancer
Novartis India announced the launch of Pluvicto(lutetium (177Lu) vipivotide tetraxetan), the country’s first regulatory authority-approved radioligand therapy for eligible patients…
